CERo Therapeutics Holdings, Inc. Warrants
CEROW
About: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Employees: 8
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
63% more capital invested
Capital invested by funds: $45.7K [Q1] → $74.5K (+$28.9K) [Q2]
32.65% more ownership
Funds ownership: 2.26% [Q1] → 34.91% (+32.65%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
12% less funds holding
Funds holding: 26 [Q1] → 23 (-3) [Q2]
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Financial journalist opinion
We haven’t received any recent news articles for CEROW